SHL Telemedicine (SHMLF) director details existing option grants

Rhea-AI Filing Summary

SHL Telemedicine Ltd director Offer Itamar reported existing option holdings, not new trades. The filing lists multiple options over Ordinary Shares, each covering 12,500 underlying shares with exercise prices of CHF 2.75 or CHF 3.25, exercisable between September 16, 2026 and September 16, 2029 and expiring on September 16, 2031.

Insider Trade Summary

8 transactions reported

Mixed 8 txns

Insider Offer Itamar

Role Director

Type	Security	Shares	Price	Value
holding	Option	--	--	--
holding	Option	--	--	--
holding	Option	--	--	--
holding	Option	--	--	--
holding	Option	--	--	--
holding	Option	--	--	--
holding	Option	--	--	--
holding	Option	--	--	--

Holdings After Transaction: Option — 12,500 shares (Direct)

Footnotes (1)

1. [object Object]

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Offer Itamar

(Last) (First) (Middle)

HATLALIM 36

(Street)

RAANANA 4356889

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SHL TELEMEDICINE LTD [ SHLT ]

3a. Foreign Trading Symbol
[SHLTN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option	09/16/2026	09/16/2031	Ordinary Shares	12,500	$3.25(1)	D
Option	09/16/2026	09/16/2031	Ordinary Shares	12,500	$2.75(1)	D
Option	09/16/2027	09/16/2031	Ordinary Shares	12,500	$3.25(1)	D
Option	09/16/2027	09/16/2031	Ordinary Shares	12,500	$2.75(1)	D
Option	09/16/2028	09/16/2031	Ordinary Shares	12,500	$3.25(1)	D
Option	09/16/2028	09/16/2031	Ordinary Shares	12,500	$2.75(1)	D
Option	09/16/2029	09/16/2031	Ordinary Shares	12,500	$3.25(1)	D
Option	09/16/2029	09/16/2031	Ordinary Shares	12,500	$2.75(1)	D

Explanation of Responses:

1. The exercise price is in CHF.

Remarks:

This Form 3 is filed pursuant to the Holding Foreign Insiders Accountable Act (HFIAA), which extends Section 16(a) reporting obligations to directors and officers of Foreign Private Issuers effective March 18, 2026.

	/s/ Offer Itamar	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the SHMLF Form 3 filing by Offer Itamar show?

The Form 3 shows director Offer Itamar’s existing option holdings in SHL Telemedicine Ltd. It lists several options over Ordinary Shares, specifying exercise prices in CHF, underlying share amounts, future exercise dates, and a common expiration date of September 16, 2031.

Did Offer Itamar buy or sell SHMLF shares in this Form 3?

No buy or sell transactions are reported in this Form 3. The entries are classified as holdings of options, with no shares acquired or disposed, and the transaction summary shows zero buy, sell, or exercise activity and only holding entries recorded.

What option terms are disclosed for SHMLF in this Form 3?

The filing discloses options over Ordinary Shares with exercise prices of CHF 2.75 and CHF 3.25. Each line reflects 12,500 underlying shares, with exercise dates ranging from September 16, 2026 to September 16, 2029 and a common expiration date of September 16, 2031.

How many derivative positions does Offer Itamar hold in SHMLF?

The derivative summary lists multiple option positions over Ordinary Shares. Each position has 12,500 underlying shares, with different exercise prices and exercise dates, all classified as directly owned options and expiring on September 16, 2031, indicating several separate grants.

In what currency are the SHMLF option exercise prices stated?

The exercise prices for Offer Itamar’s SHL Telemedicine options are stated in CHF. A footnote explicitly clarifies that the option exercise prices in the filing are denominated in Swiss francs rather than another currency such as U.S. dollars.

What does the transaction summary indicate for SHMLF’s Form 3?

The transaction summary indicates zero buys, sells, exercises, gifts, or tax withholdings and eight holding entries. This confirms the Form 3 is a baseline disclosure of existing derivative holdings, not a report of new trading activity in SHL Telemedicine’s securities.